1
|
Tunio S, Strychowsky JE, Dzioba A, You P, Madou E, Chen BA. The Use of Ipratropium Bromide for the Treatment of Pediatric Sialorrhea: A Retrospective Clinical Case Series. Ann Otol Rhinol Laryngol 2024; 133:560-565. [PMID: 38433339 PMCID: PMC11107125 DOI: 10.1177/00034894241235523] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/05/2024]
Abstract
OBJECTIVE This retrospective review documents the experience of ipratropium bromide use among pediatric patients with sialorrhea at our multidisciplinary sialorrhea clinic at Children's Hospital at London Health Sciences Centre (LHSC). METHODS A retrospective chart review of patients diagnosed with sialorrhea at our multidisciplinary clinic between January 2015 and June 2021 was completed. Data on patient demographics, comorbidities, clinical presentation, previous interventions, quality of life, and medication adverse side effects was collected. Drooling Frequency and Severity Scale (DFSS) scores were reviewed to compare sialorrhea management pre- and post-treatment with topical 0.03% ipratropium bromide nasal solution. A descriptive analysis and Wilcoxon signed rank tests were conducted to compare pre- versus post-treatment DFSS scores. RESULTS A total of 12 patients presented for follow-up and were included in the final analysis. At the pre-treatment visit, the median DFSS score was 4 for frequency and 5 for severity. Post-treatment, median DFSS score was 3 for frequency and 4.5 for severity, (P = .020 and .129, respectively). Minimal adverse effects were encountered. CONCLUSIONS Ipratropium bromide provided a statistically significant benefit for drooling frequency in the patients studied and may present an additional topical medical option for pediatric sialorrhea with limited adverse effects.
Collapse
Affiliation(s)
- Suhaima Tunio
- Schulich School of Medicine & Dentistry, Western University, London, ON, Canada
| | - Julie E. Strychowsky
- Department of Otolaryngology-Head & Neck Surgery, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada
| | - Agnieszka Dzioba
- Department of Otolaryngology-Head & Neck Surgery, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada
| | - Peng You
- Department of Otolaryngology-Head & Neck Surgery, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada
| | - Edward Madou
- Department of Otolaryngology-Head & Neck Surgery, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada
| | - Breanna A. Chen
- Department of Paediatrics, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada
- Children’s Health Research Institute, Lawson Health Research Institute, London, ON, Canada
| |
Collapse
|
2
|
Hirayama I, Kamijo Y, Nonaka M, Yano T, Ishii M, Tominaga Y. Sublingual administration of atropine eye drops for treating organophosphorus poisoning. Clin Case Rep 2024; 12:e8762. [PMID: 38681030 PMCID: PMC11052684 DOI: 10.1002/ccr3.8762] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2024] [Revised: 03/08/2024] [Accepted: 03/16/2024] [Indexed: 05/01/2024] Open
Abstract
An 89-year-old patient with fenitrothion toxicity received sublingual atropine eye drops, reducing the intravenous atropine requirement. This alternative method enabled rapid rehabilitation, and he walked unaided, leading to discharge.
Collapse
Affiliation(s)
- Ichiro Hirayama
- Department of Clinical Toxicology, Faculty of MedicineSaitama Medical UniversitySaitamaJapan
- Department of Emergency MedicineNational Hospital Organization Saitama HospitalSaitamaJapan
| | - Yoshito Kamijo
- Department of Clinical Toxicology, Faculty of MedicineSaitama Medical UniversitySaitamaJapan
| | - Minaho Nonaka
- Department of Emergency MedicineNational Hospital Organization Saitama HospitalSaitamaJapan
| | - Tetsuhiro Yano
- Department of Emergency MedicineNational Hospital Organization Saitama HospitalSaitamaJapan
| | - Mitsuru Ishii
- Department of Emergency MedicineNational Hospital Organization Saitama HospitalSaitamaJapan
| | - Yoshiteru Tominaga
- Department of Emergency MedicineNational Hospital Organization Saitama HospitalSaitamaJapan
| |
Collapse
|
3
|
Parrot M, Yathavan B, Averin O, Hoggard L, Rower JE, Voight M, Greene D, Tarrell A, Whelan A, Ghandehari H, Murphy N, Yellepeddi V. Clinical pharmacokinetics of atropine oral gel formulation in healthy volunteers. Clin Transl Sci 2024; 17:e13753. [PMID: 38465519 PMCID: PMC10926053 DOI: 10.1111/cts.13753] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2023] [Revised: 02/01/2024] [Accepted: 02/14/2024] [Indexed: 03/12/2024] Open
Abstract
Sialorrhea or drooling is a common problem in children and adults with neurodevelopmental disorders. It can negatively impact the quality of life due to its physical and psychological manifestations. Providers commonly prescribe atropine eye drops for topical administration to the oral mucosa, as an off-label treatment to manage sialorrhea. However, the off-label use of atropine eye drops can be associated with medication and dosing errors and systemic side effects. To address these limitations of treatment, we developed a mucoadhesive topical oral gel formulation of atropine as an alternative route to off-label administration of atropine eye drops. In this clinical pharmacokinetic (PK) study, we evaluated the safety and PK of atropine gel (0.01% w/w) formulation after single-dose administration to the oral mucosa in 10 healthy volunteers. The PK data showed that after topical administration to the oral mucosa, atropine followed a two-compartment PK profile. The maximum plasma concentration and area under the curve extrapolated to infinite time were 0.14 ng/mL and 0.74 h·ng·mL-1 , respectively. The absorption rate constant calculated by the compartmental analysis was 0.4 h-1 . Safety parameters, such as heart rate, blood pressure, and oxygen saturation, did not significantly change before and after administration of the gel formulation, and no adverse events were observed in all participants who received atropine gel. These data indicate that atropine gel formulation has a satisfactory PK profile, is well-tolerated at the dose studied, and can be further considered for clinical development as a drug product to treat sialorrhea.
Collapse
Affiliation(s)
- Madison Parrot
- Division of Clinical Pharmacology, Department of Pediatrics, Spencer Fox Eccles School of MedicineUniversity of UtahSalt Lake CityUtahUSA
- Department of Molecular Pharmaceutics, Utah Center for Nanomedicine, College of PharmacyUniversity of UtahSalt Lake CityUtahUSA
| | - Bhuvanesh Yathavan
- Department of Molecular Pharmaceutics, Utah Center for Nanomedicine, College of PharmacyUniversity of UtahSalt Lake CityUtahUSA
| | - Olga Averin
- Department of Pharmacology and Toxicology and Center for Human ToxicologyUniversity of UtahSalt Lake CityUtahUSA
| | - Logan Hoggard
- Department of Pharmacology and Toxicology and Center for Human ToxicologyUniversity of UtahSalt Lake CityUtahUSA
| | - Joseph E. Rower
- Department of Pharmacology and Toxicology and Center for Human ToxicologyUniversity of UtahSalt Lake CityUtahUSA
| | - Michael Voight
- Investigational Drug Service, Pharmacy Services, University of Utah HospitalSalt Lake CityUtahUSA
| | - Danielle Greene
- Division of Clinical Pharmacology, Department of Pediatrics, Spencer Fox Eccles School of MedicineUniversity of UtahSalt Lake CityUtahUSA
| | - Ariel Tarrell
- Division of Clinical Pharmacology, Department of Pediatrics, Spencer Fox Eccles School of MedicineUniversity of UtahSalt Lake CityUtahUSA
| | - Aviva Whelan
- Division of Clinical Pharmacology, Department of Pediatrics, Spencer Fox Eccles School of MedicineUniversity of UtahSalt Lake CityUtahUSA
| | - Hamidreza Ghandehari
- Department of Molecular Pharmaceutics, Utah Center for Nanomedicine, College of PharmacyUniversity of UtahSalt Lake CityUtahUSA
| | - Nancy Murphy
- Division of Complex Care, Department of PediatricsUniversity of Utah HealthSalt Lake CityUtahUSA
| | - Venkata Yellepeddi
- Division of Clinical Pharmacology, Department of Pediatrics, Spencer Fox Eccles School of MedicineUniversity of UtahSalt Lake CityUtahUSA
- Department of Molecular Pharmaceutics, Utah Center for Nanomedicine, College of PharmacyUniversity of UtahSalt Lake CityUtahUSA
| |
Collapse
|
4
|
Petkus KD, Noritz G, Glader L. Examining the Role of Sublingual Atropine for the Treatment of Sialorrhea in Patients with Neurodevelopmental Disabilities: A Retrospective Review. J Clin Med 2023; 12:5238. [PMID: 37629280 PMCID: PMC10455410 DOI: 10.3390/jcm12165238] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2023] [Revised: 08/04/2023] [Accepted: 08/09/2023] [Indexed: 08/27/2023] Open
Abstract
Sialorrhea is common in children with neurodevelopmental disabilities (NDD) and is reported in >40% of children with cerebral palsy (CP). It causes a range of complications, including significant respiratory morbidity. This single-center retrospective chart review aims to document sublingual atropine (SLA) utilization to guide further study in establishing its role in secretion management for children with NDD. A chart review was completed for patients with NDD ≤ 22 years of age treated with SLA at a free-standing children's hospital between 1 January 2016 and 1 June 2021. Descriptive statistics were generated to summarize findings. In total, 190 patients were identified, of which 178 met inclusion criteria. The average starting dose for SLA was 1.5 mg/day, or 0.09 mg/kg/day when adjusted for patient weight. Eighty-nine (50%) patients were prescribed SLA first line for secretion management while 85 (48%) patients tried glycopyrrolate prior to SLA. SLA was used after salivary Botox, ablation, and/or surgery in 16 (9%) patients. This study investigates SLA as a potential pharmacologic agent to treat sialorrhea in children with NDD. We identify a range of prescribing patterns regarding dosing, schedule, and place in therapy, highlighting the need for further evidence to support and guide its safe and efficacious use.
Collapse
Affiliation(s)
- Kayla Durkin Petkus
- Division of Complex Care, Nationwide Children’s Hospital, Columbus, OH 43205, USA; (G.N.); (L.G.)
- Department of Pharmacy, Nationwide Children’s Hospital, Columbus, OH 43205, USA
| | - Garey Noritz
- Division of Complex Care, Nationwide Children’s Hospital, Columbus, OH 43205, USA; (G.N.); (L.G.)
| | - Laurie Glader
- Division of Complex Care, Nationwide Children’s Hospital, Columbus, OH 43205, USA; (G.N.); (L.G.)
| |
Collapse
|
5
|
Perez G, Young L, Kravitz R, Sheehan D, Adang L, Van Haren K, Lin JL, Jaffe NN, Kuo D, Ball L, Keller J, Sank J, DiVito D, Naime S. Pulmonological issues. Curr Probl Pediatr Adolesc Health Care 2022; 52:101313. [PMID: 36470809 PMCID: PMC11348663 DOI: 10.1016/j.cppeds.2022.101313] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Pediatric leukodystrophies are rare neurodegenerative diseases involving multiple systems. Each form has unique neurologic features but are characterized by encephalopathy with accompanying impairments evidenced in reflexes, muscle tone and movement control. Weakness of expiratory, inspiratory, and upper airway muscles may lead to impaired airway secretion clearance resulting in recurrent respiratory infections, dysphagia, sleep-disordered breathing, restrictive lung disease, and ultimately chronic respiratory insufficiency.
Collapse
Affiliation(s)
| | - Lisa Young
- Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | | | | | - Laura Adang
- Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | | | - Jody L Lin
- Universty of Utah, Salt Lake City, UT, USA
| | | | - Dennis Kuo
- Strong Memorial Hospital, Rochester, NY, USA
| | - Laura Ball
- Children's National Medical Center, Washington DC, USA
| | | | | | - Donna DiVito
- Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | | |
Collapse
|
6
|
Use of Sublingual Atropine Drops in Clozapine-Associated Sialorrhea in an Adolescent Patient: A Case Report. J Clin Psychopharmacol 2022; 42:606-607. [PMID: 36251377 DOI: 10.1097/jcp.0000000000001616] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
7
|
Sublingual Atropine Administration as a Tool to Decrease Salivary Glands' PSMA-Ligand Uptake: A Preclinical Proof of Concept Study Using [ 68Ga]Ga-PSMA-11. Pharmaceutics 2022; 14:pharmaceutics14061276. [PMID: 35745848 PMCID: PMC9230580 DOI: 10.3390/pharmaceutics14061276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2022] [Revised: 06/06/2022] [Accepted: 06/13/2022] [Indexed: 02/04/2023] Open
Abstract
Prostate Specific Membrane Antigen (PSMA)-directed radionuclide therapy has gained an important role in the management of advanced castration-resistant prostate cancer. Although extremely promising, the prolongation in survival and amelioration of disease-related symptoms must be balanced against the direct toxicities of the treatment. Xerostomia is amongst the most common and debilitating of these, particularly when using an alpha emitter. It is therefore of main importance to develop new preventive strategies. This preclinical study has evaluated the effect of α-adrenergic and anticholinergic drugs on [99mTc]TcO4− Single Photon Emission Computed Tomography/Computed Tomography (SPECT/CT) and [68Ga]Ga-PSMA-11 Positron Emission Tomography (PET/CT). Methods: The effects of phenylephrine, scopolamine, atropine, and ipratropium on salivary glands uptake were evaluated in non-tumor-bearing mice by [99mTc]TcO4− microSPECT/CT. The most efficient identified strategy was evaluated in non-tumor-bearing and xenografted mice by [68Ga]Ga-PSMA-11 PET/CT. Results: Scopolamine and atropine showed a significant decrease in the parotid glands’ uptake on SPECT/CT whereas phenylephrine and ipratropium failed. Atropine premedication (sublingual route), which was the most effective strategy, also showed a drastic decrease of [68Ga]Ga-PSMA-11 salivary glands’ uptake in both non-tumor-bearing mice (−51.6% for the parotids, p < 0.0001) and human prostate adenocarcinoma xenografted mice (−26.8% for the parotids, p < 0.0001). Conclusion: Premedication with a local administration of atropine could represent a simple, safe, and efficient approach for reducing salivary glands’ uptake.
Collapse
|
8
|
You P, Strychowsky J, Gandhi K, Chen BA. Anticholinergic treatment for sialorrhea in children: A systematic review. Paediatr Child Health 2022; 27:82-87. [PMID: 35599670 PMCID: PMC9113838 DOI: 10.1093/pch/pxab051] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2021] [Accepted: 07/09/2021] [Indexed: 08/27/2023] Open
Abstract
Background Sialorrhea in children can be associated with adverse physical and social effects. Treatment using anticholinergic medications has been shown to offer symptomatic relief, but there is no consensus regarding which treatment is the most efficacious. Objective To examine the effectiveness of anticholinergic medications for sialorrhea in children. Methods A systematic review was carried out in Medline, EMBASE, Cochrane, Scopus, and the Web of Science from inception until April 29, 2020. Studies reporting original data on the efficacy of anticholinergic medications in the management of sialorrhea in children aged 0 to 17 years of age were included. This review adhered to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) standards. Data on study design, setting, population, pharmacologic intervention(s), comparator(s), outcomes, and results were extracted and summarized. Results The search strategy identified 2,800 studies of which 27 articles were included in the synthesis, including five randomized controlled trials. Each anticholinergic undergoing experimental study (glycopyrrolate, scopolamine/hyoscine, trihexyphenidyl/benzhexol, benztropine, and atropine) showed evidence of efficacy. Adverse side effects were common. Significant heterogeneity exists in the studies' methodology and the variability of outcome measures used between studies precluded a meta-analysis. Conclusions Glycopyrrolate, scopolamine/hyoscine, trihexyphenidyl/benzhexol, benztropine, and atropine have all shown efficacy in the treatment of sialorrhea in children. The small number of reports and the variability in study design precluded a meta-analysis. More studies are needed with uniformity in outcome measures to help guide evidence-based decision making. A guidance table is presented.
Collapse
Affiliation(s)
- Peng You
- Department of Otolaryngology - Head and Neck Surgery, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada
| | - Julie Strychowsky
- Department of Otolaryngology - Head and Neck Surgery, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada
| | - Karan Gandhi
- Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada
| | - Breanna A Chen
- Department of Paediatrics, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada
- Children’s Health Research Institute, Lawson Health Research Institute, London, Ontario, Canada
| |
Collapse
|
9
|
Veldhuijzen van Zanten S, Ferretti E, MacLean G, Daboval T, Lauzon L, Reuvers E, Vadeboncoeur C. Medications to manage infant pain, distress and end-of-life symptoms in the immediate postpartum period. Expert Opin Pharmacother 2021; 23:43-48. [PMID: 34384318 DOI: 10.1080/14656566.2021.1965574] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
INTRODUCTION Perinatal palliative care (PnPC) is a growing field where healthcare providers from multiple disciplines are supporting families and providing holistic care for their babies with life-limiting illnesses. It is important to have an approach that includes the standardized management of end-of-life symptoms that are anticipated around the time of birth. AREAS COVERED A need was identified to develop medication orders for the initial pharmacological management of symptoms at end-of-life for infants with life-limiting conditions intended for use outside of an intensive care setting. The choice of medications was based on a review of the literature, discussion with content experts and guided by their ease of use, accessibility and noninvasive route of delivery. The recommendations can be used as a guide for the initial management of common symptoms encountered in perinatal palliative care. EXPERT OPINION There are studies looking at many qualitative aspects of perinatal palliative care including perceptions of care, decision-making, and bereavement; however, few specifically focus on symptom management in the delivery room and postpartum ward settings. There is a need for standardization of the medical management of infants born with life-limiting conditions whose parents choose to pursue palliative care.
Collapse
Affiliation(s)
- Stephanie Veldhuijzen van Zanten
- University Of Ottawa, Ottawa, ON, Canada.,Pediatric Palliative Care Program, Children's Hospital of Eastern Ontario and Roger Neilson House, Ottawa, ON, Canada
| | - Emanuela Ferretti
- Pediatrics, University Of Ottawa, Ottawa, ON, Canada.,Department Of Pediatrics, Division Of Neonatology, Children's Hospital Of Eastern Ontario, Ottawa, ON, Canada
| | - Gillian MacLean
- Queen's University, Kingston, ON, Canada.,Department of Pediatrics, Division of Neonatology, Kingston Health Sciences Centre, Kingston, ON, Canada
| | - Thierry Daboval
- University Of Ottawa, Ottawa, ON, Canada.,Department Of Pediatrics, Division Of Neonatology, Children's Hospital Of Eastern Ontario, Ottawa, ON, Canada
| | - Lena Lauzon
- Neonatal Intensive Care Pharmacist, Children's Hospital Of Eastern Ontario, Ottawa, ON, Canada
| | - Emily Reuvers
- Clinical Care Leader, The Ottawa Hospital, Ottawa, ON, Canada
| | - Christina Vadeboncoeur
- University Of Ottawa, Ottawa, ON, Canada.,Pediatric Palliative Care Program, Children's Hospital of Eastern Ontario and Roger Neilson House, Ottawa, ON, Canada
| |
Collapse
|
10
|
Michelon H, Larabi IA, Lemoine J, Alvarez JC, Genevée A, Lillo-Lelouet A, Azouvi P, Lefèvre-Dognin C, Paquereau J. Atropine-induced toxicity after off-label sublingual administration of eyedrop for sialorrhoea treatment in neurological disabled patients. Br J Clin Pharmacol 2021; 87:3364-3369. [PMID: 33521988 DOI: 10.1111/bcp.14757] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2020] [Revised: 01/12/2021] [Accepted: 01/20/2021] [Indexed: 11/28/2022] Open
Abstract
Sialorrhea is a troublesome and disabling symptom defined by the unintentional loss of saliva from the mouth, usually associated with swallowing disorders. Today there is no consensus about the management of sialorrhoea, but off-label use of ophthalmic atropine eyedrop administered sublingually may offer benefits, despite limited safety data. We report 2 cases of atropine overdose after sublingual administration illustrating that atropine can expose to severe adverse effects when administered sublingually. The noncompartmental pharmacokinetic study of atropine performed in 1 patient highlighted that systemic absorption of sublingual atropine was effective (Cmax [1 h] = 2.2 ng mL-1 ; approximately) after a single dose of 1 mg.
Collapse
Affiliation(s)
- Hugues Michelon
- Service de Pharmacie, Hôpital Sainte-Périne, APHP. Université Paris-Saclay, Paris, France.,Service de Pharmacie, Hôpital Raymond Poincaré, APHP. Université Paris-Saclay, Garches, France
| | - Islam Amine Larabi
- Service de Pharmacologie - Toxicologie, Hôpital Raymond Poincaré, APHP. Université Paris-Saclay, Garches, France
| | - Jérôme Lemoine
- Unité de Soins de Rééducation Post-Réanimation, Hôpital Raymond Poincaré, APHP. Université Paris-Saclay, Garches, France
| | - Jean-Claude Alvarez
- Service de Pharmacologie - Toxicologie, Hôpital Raymond Poincaré, APHP. Université Paris-Saclay, Garches, France
| | - Anne Genevée
- Unité de Soins de Rééducation Post-Réanimation, Hôpital Raymond Poincaré, APHP. Université Paris-Saclay, Garches, France
| | - Agnès Lillo-Lelouet
- Centre Régional de Pharmacovigilance de Paris, Hôpital Européen Georges Pompidou, AP-HP.Centre - Université de Paris, Paris, France
| | - Philippe Azouvi
- Unité de Soins de Rééducation Post-Réanimation, Hôpital Raymond Poincaré, APHP. Université Paris-Saclay, Garches, France
| | - Clémence Lefèvre-Dognin
- Unité de Soins de Rééducation Post-Réanimation, Hôpital Raymond Poincaré, APHP. Université Paris-Saclay, Garches, France.,Unité de Soins Prolongés Complexes, Hôpital Sainte-Périne, APHP. Université Paris-Saclay, Paris, France
| | - Julie Paquereau
- Unité de Soins de Rééducation Post-Réanimation, Hôpital Raymond Poincaré, APHP. Université Paris-Saclay, Garches, France
| |
Collapse
|
11
|
Abolghasemi MM, Taheri H, Aghaee A. Determination of the scopolamine in Datura innoxia based on quick, easy, cheap, effective, rugged and safe (QuEChERS) extraction followed by HPLC-PDA. SEP SCI TECHNOL 2020. [DOI: 10.1080/01496395.2020.1839773] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Affiliation(s)
| | - Hoda Taheri
- Department of Chemistry, Faculty of Science, University of Maragheh, Maragheh, Iran
| | - Ahmad Aghaee
- Department of Biology, Faculty of Science, University of Maragheh, Maragheh, Iran
| |
Collapse
|
12
|
Azapağası E, Kendirli T, Perk O, Kutluk G, Öz Tunçer G, Teber S, Çobanoğlu N. Sublingual Atropine Sulfate Use for Sialorrhea in Pediatric Patients. J Pediatr Intensive Care 2020; 9:196-200. [PMID: 32685247 DOI: 10.1055/s-0040-1708552] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2019] [Accepted: 02/16/2020] [Indexed: 10/24/2022] Open
Abstract
Sialorrhea is a frequent problem and may lead to aspiration in patients with swallowing dysfunction. We aimed to assess the effectiveness and safety of sublingual atropine sulfate treatment in pediatric patients with sialorrhea. The medical records of patients who had received sublingual atropine sulfate between January 2015 and January 2016 were reviewed retrospectively. The demographic properties, diagnosis, invasive or noninvasive mechanical ventilation need, and the presence of tracheotomy were assessed. Response rates to sublingual atropine were measured using the Teacher Drooling Scale (TDS). Pre and post-treatment drooling scores were compared. Atropine sulfate ampoule was administered at 20 µg/kg/dose. Minimum dose was 0.25 mg, while maximum dose was 0.03 mg/kg.Thirty-five pediatric patients with sialorrhea who had received sublingual atropine sulfate were identified; however, TDS scores had been recorded in only 20 of them. The median age of the patients was 25 months (3-78 months; 7 girls, 13 boys). Sixteen (80%) patients were on invasive mechanical ventilation and seven (30%) had tracheotomy. Nineteen patients had a neurodevelopmental disorder and only one patient had oral and esophageal lesions due to corrosive material intake. The median TDS score prior to sublingual atropine sulfate treatment was 5, and it decreased to 3 on the second day of treatment, a change that was statistically significant ( p < 0.001). No side effects were observed. Sublingual atropine sulfate is safe and effective in the short-term treatment of sialorrhea; however, randomized placebo controlled and long-term follow-up studies are necessary.
Collapse
Affiliation(s)
- Ebru Azapağası
- Department of Pediatric Intensive Care, Ankara University Medical Faculty, Ankara, Turkey
| | - Tanıl Kendirli
- Department of Pediatric Intensive Care, Ankara University Medical Faculty, Ankara, Turkey
| | - Oktay Perk
- Department of Pediatric Intensive Care, Ankara University Medical Faculty, Ankara, Turkey
| | - Gültekin Kutluk
- Department of Pediatric Neurology, Ankara University Medical Faculty, Ankara, Turkey
| | - Gökçen Öz Tunçer
- Department of Pediatric Neurology, Ankara University Medical Faculty, Ankara, Turkey
| | - Serap Teber
- Department of Pediatric Neurology, Ankara University Medical Faculty, Ankara, Turkey
| | - Nazan Çobanoğlu
- Department of Pediatric Pulmonology, Ankara University Medical Faculty, Ankara, Turkey
| |
Collapse
|
13
|
Van der Poorten T, De Hert M. The sublingual use of atropine in the treatment of clozapine-induced sialorrhea: A systematic review. Clin Case Rep 2019; 7:2108-2113. [PMID: 31788260 PMCID: PMC6878073 DOI: 10.1002/ccr3.2431] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2019] [Revised: 07/29/2019] [Accepted: 08/06/2019] [Indexed: 12/31/2022] Open
Abstract
Clozapine is considered the golden standard in the treatment of therapy-resistant schizophrenia; however, it associated with bothersome side effects such as sialorrhea. Current evidence suggests that the sublingual use of atropine seems to be safe and effective and could be considered as a first-line treatment of clozapine-induced sialorrhea.
Collapse
Affiliation(s)
| | - Marc De Hert
- Department Of NeurosciencesKU LeuvenKortenbergBelgium
- University of AntwerpAntwerpBelgium
| |
Collapse
|
14
|
|
15
|
Aodah A, Rawas-Qalaji M, Bafail R, Rawas-Qalaji M. Effect of Fast-Disintegrating Tablets' Characteristics on the Sublingual Permeability of Atropine Sulfate for the Potential Treatment of Organophosphates Toxicity. AAPS PharmSciTech 2019; 20:229. [PMID: 31227930 DOI: 10.1208/s12249-019-1420-1] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2019] [Accepted: 05/16/2019] [Indexed: 11/30/2022] Open
Abstract
Atropine sulfate (AS) fast-disintegrating sublingual tablets (FDSTs) were tested for AS sublingual permeation's feasibility as a potential alternative dosage form to treat organophosphates (OP) toxicity. More than 12,000 OP pesticide toxicity cases were reported in the USA from 2011 to 2014. AS is the recommended antidote for OP toxicity; however, it is only available as an ATROPEN® auto-injector, an IM injection, for self-administration, which is associated with several drawbacks and limitations. Six AS FDST batches were formulated and characterized. Two tablet sizes, group A weighing 150 mg and group B weighing 50 mg, were formulated with three different AS doses: 2 mg (A1 and B1), 4 mg (A2 and B2), and 8 mg (A3 and B3). AS in vitro diffusion and sublingual permeation were investigated in Franz cells using a cellulose membrane and an excised porcine sublingual membrane. The effect of AS load and tablet size on sublingual permeation was also evaluated. All batches passed quality control tests. AS FDSTs' size and AS load had a significant effect on tablet disintegration time and drug dissolution, which significantly impacted AS concentration gradient across the diffusional membrane. Group B FDSTs (smaller tablets) resulted in a significantly higher initial permeation (JAUC0-15) compared to group A FDSTs. Also, the cumulative AS (JAUC0-90) and AS influx (J) increased linearly with increasing AS dose. These AS FDSTs have the potential to be explored in vivo to determine the required bioequivalent sublingual AS dose as an alternative dosage form for the treatment of OP toxicity.
Collapse
|
16
|
Dias BLS, Fernandes AR, Maia Filho HDS. Treatment of drooling with sublingual atropine sulfate in children and adolescents with cerebral palsy. ARQUIVOS DE NEURO-PSIQUIATRIA 2017; 75:282-287. [DOI: 10.1590/0004-282x20170033] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/12/2016] [Accepted: 12/20/2016] [Indexed: 11/21/2022]
Abstract
ABSTRACT Atropine sulfate blocks the muscarinic receptors in the salivary glands and leads to reduced saliva production. There are no published studies about its use in children with cerebral palsy. Objective To report the effect of sublingual atropine sulfate to treat drooling in children with cerebral palsy by comparing the results of the Drooling Impact Scale in a non-controlled open clinical trial. Results Twenty-five children were assessed. The difference in the mean scores of the pre- and post-treatment scales reached statistical significance. There was a low frequency of side effects compared to studies with other anticholinergics. Conclusion The use of sublingual atropine sulfate seems to be safe and there is a reduction in the Drooling Impact Scale score, which suggests efficacy in the treatment of drooling in children and adolescents with cerebral palsy. Our results should be replicated in randomized, placebo-controlled studies with larger numbers of participants.
Collapse
|
17
|
Norderyd J, Graf J, Marcusson A, Nilsson K, Sjöstrand E, Steinwall G, Ärleskog E, Bågesund M. Sublingual administration of atropine eyedrops in children with excessive drooling - a pilot study. Int J Paediatr Dent 2017; 27:22-29. [PMID: 26708211 PMCID: PMC5324542 DOI: 10.1111/ipd.12219] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
BACKGROUND Drooling can be a severe disability and have high impact on daily life. Reversible treatment is preferable. AIM To analyse whether sublingual administration of atropine eyedrops is a useful reversible treatment option for severe drooling in children with disabilities. DESIGN The study had a prospective, single-system research design. The participants served as their own controls. The study period was 3 weeks without treatment, 4 weeks with atropine eyedrop solution 10 mg/mL one drop a day followed by 4 weeks of one drop twice a day. Parents' rating of their child's drooling was assessed on a 100-mm VAS, and unstimulated salivary secretion rate measurement was performed together with notations about side effects and practicality. RESULTS Parents' VAS assessment of drooling decreased from a median (range) of 74 (40-98) at baseline to 48 (18-88) (P = 0.05) and 32 (12-85) (P = 0.004) after 4 weeks of atropine once a day and another 4 weeks of atropine twice a day, respectively (n = 11). Unstimulated salivary secretion rates decreased from baseline to end of study (P = 0.032). Several parents complained about difficult administration. No irreversible side effects were noted. CONCLUSIONS Sublingual atropine eyedrops may be an alternative for treatment of severe drooling in children with disabilities.
Collapse
Affiliation(s)
- Johanna Norderyd
- National Oral Disability Centre for Rare DisordersThe Institute for Postgraduate Dental EducationJönköpingSweden,CHILD, Swedish Institute for Disability ResearchJönköping UniversityJönköpingSweden
| | - Jonas Graf
- Department of Otorhinolaryngology and Department of Clinical and Experimental MedicineLinköping UniversityLinköpingSweden
| | - Agneta Marcusson
- Department of Dentofacial OrthopedicsMaxillofacial UnitLinköping UniversityLinköpingSweden
| | | | - Eva Sjöstrand
- Department for Child and Youth HabilitationCounty Council of ÖstergötlandLinköpingSweden
| | | | - Elinor Ärleskog
- Department of Oral & Maxillofacial SurgeryLinköping University HospitalLinköpingSweden
| | - Mats Bågesund
- Centre for Orthodontics and Paediatric Dentistry and Department of Medical and Health SciencesLinköping UniversityLinköpingSweden
| |
Collapse
|
18
|
Dias BLS, Fernandes AR, Maia Filho HDS. Sialorrhea in children with cerebral palsy. J Pediatr (Rio J) 2016; 92:549-558. [PMID: 27281791 DOI: 10.1016/j.jped.2016.03.006] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/28/2016] [Revised: 03/07/2016] [Accepted: 03/09/2016] [Indexed: 01/19/2023] Open
Abstract
OBJECTIVE To review the literature on sialorrhea in children with cerebral palsy. SOURCE OF DATA Non-systematic review using the keywords "sialorrhea" and "child" carried out in the PubMed®, LILACS®, and SciELO® databases during July 2015. A total of 458 articles were obtained, of which 158 were analyzed as they were associated with sialorrhea in children; 70 had content related to sialorrhea in cerebral palsy or the assessment and treatment of sialorrhea in other neurological disorders, which were also assessed. DATA SYNTHESIS The prevalence of sialorrhea is between 10% and 58% in cerebral palsy and has clinical and social consequences. It is caused by oral motor dysfunction, dysphagia, and intraoral sensitivity disorder. The severity and impact of sialorrhea are assessed through objective or subjective methods. Several types of therapeutic management are described: training of sensory awareness and oral motor skills, drug therapy, botulinum toxin injection, and surgical treatment. CONCLUSIONS The most effective treatment that addresses the cause of sialorrhea in children with cerebral palsy is training of sensory awareness and oral motor skills, performed by a speech therapist. Botulinum toxin injection and the use of anticholinergics have a transient effect and are adjuvant to speech therapy; they should be considered in cases of moderate to severe sialorrhea or respiratory complications. Atropine sulfate is inexpensive and appears to have good clinical response combined with good safety profile. The use of trihexyphenidyl for the treatment of sialorrhea can be considered in dyskinetic forms of cerebral palsy or in selected cases.
Collapse
Affiliation(s)
| | | | - Heber de Souza Maia Filho
- Universidade Federal Fluminense (UFF), Programa de Mestrado Profissional em Saúde Materno-Infantil, Niterói, RJ, Brazil
| |
Collapse
|
19
|
Scofano Dias BL, Fernandes AR, Maia Filho HDS. Sialorrhea in children with cerebral palsy. JORNAL DE PEDIATRIA (VERSÃO EM PORTUGUÊS) 2016. [DOI: 10.1016/j.jpedp.2016.06.002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
|
20
|
Amin R, Al-Saleh S, Narang I. Domiciliary noninvasive positive airway pressure therapy in children. Pediatr Pulmonol 2016; 51:335-48. [PMID: 26663667 DOI: 10.1002/ppul.23353] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/18/2015] [Revised: 11/09/2015] [Accepted: 11/21/2015] [Indexed: 12/28/2022]
Abstract
There has been a dramatic increase in the past few decades in the number of children receiving noninvasive positive airway pressure (PAP) therapy at home. Although PAP therapy was first prescribed for children with obstructive sleep apnea, the indications have rapidly widened to include treatment for central hypoventilation syndromes, neuromuscular and chest wall disorders as well as primary respiratory diseases. Given the rapidly expanding use of PAP therapy in children, pediatric pulmonologists need to be familiar with the indications, technical and safety considerations as well as potential complications and challenges that may arise when caring for children using PAP therapy. This review article covers the definition of PAP therapy, modes, interfaces, devices, indications, contraindications, suggested settings, complications as well as the factors influencing the adherence.
Collapse
Affiliation(s)
- Reshma Amin
- Division of Respiratory Medicine, The Hospital for Sick Children, Toronto, Canada.,Department of Paediatrics, University of Toronto, Toronto, Canada.,Department of Child Health and Evaluative Sciences, The Hospital for Sick Children, Toronto, Canada
| | - Suhail Al-Saleh
- Division of Respiratory Medicine, The Hospital for Sick Children, Toronto, Canada.,Department of Paediatrics, University of Toronto, Toronto, Canada.,Department of Physiology and Experimental Medicine, The Hospital for Sick Children, Toronto, Canada
| | - Indra Narang
- Division of Respiratory Medicine, The Hospital for Sick Children, Toronto, Canada.,Department of Paediatrics, University of Toronto, Toronto, Canada.,Department of Physiology and Experimental Medicine, The Hospital for Sick Children, Toronto, Canada
| |
Collapse
|
21
|
Initial experience from a multidisciplinary pediatric salivary gland disorder clinic. Int J Pediatr Otorhinolaryngol 2015; 79:1505-9. [PMID: 26231740 DOI: 10.1016/j.ijporl.2015.06.038] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/21/2015] [Revised: 06/24/2015] [Accepted: 06/25/2015] [Indexed: 12/14/2022]
Abstract
OBJECTIVE This study is the first in the literature to characterize and detail the clinical and surgical experience of one of the few multidisciplinary salivary gland disorder clinics in North America. METHODS This is a retrospective chart review of a descriptive nature, including patient information from February 2013 to August 2014. The Salivary Gland Disorder Clinic (SGDC) is located at Nationwide Children's Hospital, a public academic hospital. All patients seen at the SGDC were included in this study, 54 in total. Patients were seen for any salivary gland disorder presentation, ranging from sialorrhea to glandular masses. RESULTS A total of 70.4% of patients presented to the SGDC with a chief complaint of sialorrhea. Nearly 28% had previously experienced documented aspiration, and drooling severity and frequency was 4.06 and 3.3 on the Thomas-Stonell and Greenberg Drooling Rating Scales. 50% of patients presented with neurologic comorbidities and 25.9% with aerodigestive tract anatomic defects. Over 35% of patients had previously attempted medical treatment and 31.5% had no prior treatment attempts. 87% of all patients were offered further treatment options, including interventional, surgical, medical, and conservative measures. CONCLUSIONS Pediatric salivary gland disorders, especially sialorrhea, can profoundly impact overall health and quality of life. Appropriate management of this symptom requires expert training and knowledge of the upper aerodigestive tract anatomy and appropriate treatment modalities. Our study demonstrates that there is community need for a centralized salivary gland disorder clinic given the complex comorbidities and social challenges that face this population. Many patients present with great risk for aspiration-related complications and the vast majority are offered new treatment options.
Collapse
|
22
|
Weiss K, Gonzalez A, Lopez G, Pedoeim L, Groden C, Sidransky E. The clinical management of Type 2 Gaucher disease. Mol Genet Metab 2015; 114:110-122. [PMID: 25435509 PMCID: PMC4312716 DOI: 10.1016/j.ymgme.2014.11.008] [Citation(s) in RCA: 61] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/23/2014] [Revised: 11/06/2014] [Accepted: 11/07/2014] [Indexed: 12/12/2022]
Abstract
Gaucher disease, the inherited deficiency of the enzyme glucocerebrosidase, is the most common of the lysosomal storage disorders. Type 2 Gaucher disease, the most severe and progressive form, manifests either prenatally or in the first months of life, followed by death within the first years of life. The rarity of the many lysosomal storage disorders makes their diagnosis a challenge, especially in the newborn period when the focus is often on more prevalent illnesses. Thus, a heightened awareness of the presentation of these rare diseases is necessary to ensure their timely consideration. This review, designed to serve as a guide to physicians treating newborns and infants with Gaucher disease, discusses the presenting manifestations of Type 2 Gaucher disease, the diagnostic work-up, associated genotypes and suggestions for management. We also address the ethical concerns that may arise with this progressive and lethal disorder, since currently available treatments may prolong life, but do not impact the neurological manifestations of the disease.
Collapse
Affiliation(s)
- Karin Weiss
- Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
| | - Ashley Gonzalez
- Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
| | - Grisel Lopez
- Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
| | - Leah Pedoeim
- Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
| | - Catherine Groden
- Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
| | - Ellen Sidransky
- Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
| |
Collapse
|
23
|
Delgado-Charro MB, Guy RH. Effective use of transdermal drug delivery in children. Adv Drug Deliv Rev 2014; 73:63-82. [PMID: 24333231 DOI: 10.1016/j.addr.2013.11.014] [Citation(s) in RCA: 63] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2013] [Accepted: 11/29/2013] [Indexed: 12/16/2022]
Abstract
Transdermal administration offers a non-invasive and convenient method for paediatric drug delivery. The competent skin barrier function in term infants and older children limits both water loss and the percutaneous entry of chemicals including drugs; but the smaller doses required by children eases the attainment of therapeutic concentrations. Transdermal patches used in paediatrics include fentanyl, buprenorphine, clonidine, scopolamine, methylphenidate, oestrogens, nicotine and tulobuterol. Some patches have paediatric labelling supported by clinical trials whereas others are used unlicensed. Innovative drug delivery methods, such as microneedles and sonophoresis are being tested for their safety and efficacy; needleless injectors are primarily used to administer growth hormone; and two iontophoretic devices were approved for paediatrics. In contrast, the immature and rapidly evolving skin barrier function in premature neonates represents a significant formulation challenge. Unfortunately, this population group suffers from an absence of approved transdermal formulations, a shortcoming exacerbated by the significant risk of excessive drug exposure via the incompletely formed skin barrier.
Collapse
|
24
|
Heisler M, Hamilton G, Abbott A, Chengalaram A, Koceja T, Gerkin R. Randomized double-blind trial of sublingual atropine vs. placebo for the management of death rattle. J Pain Symptom Manage 2013; 45:14-22. [PMID: 22795904 DOI: 10.1016/j.jpainsymman.2012.01.006] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/11/2011] [Revised: 12/30/2011] [Accepted: 01/19/2012] [Indexed: 10/28/2022]
Abstract
CONTEXT Noisy breathing because of respiratory tract secretions (RTS), often referred to as "death rattle," occurs in up to half of all dying patients. Despite a lack of evidence showing benefit compared with placebo, antimuscarinic medications have been used in an attempt to decrease noise associated with RTS and to decrease family distress. OBJECTIVES The goal of this study was to compare the efficacy of the antimuscarinic medication atropine with that of placebo in reducing noise associated with death rattle. METHODS Terminally ill adult hospice inpatients who developed noisy breathing as a result of RTS were randomized to double-blind treatment with atropine or placebo. Study drug was given as a single sublingual dose. Noise from breathing was monitored at baseline and at two and four hours. RESULTS One hundred thirty-seven participants were randomized to atropine or placebo. Reduction in noise score from baseline to two hours after dose occurred in 37.8% and 41.3% of subjects treated with atropine and placebo, respectively (P=0.73). Noise score reduction at four hours occurred in 39.7% and 51.7% of subjects treated with atropine and placebo, respectively (P=0.21). Differences between groups were not significant at either time point. Atropine was well tolerated. Heart rate increased slightly in both groups (+1.1/minute for atropine and +3.1/minute for placebo) but not significantly. CONCLUSION Sublingual atropine given as a single dose was not more effective than placebo in reducing the noise associated with death rattle.
Collapse
Affiliation(s)
- Mark Heisler
- Hospice of the Valley, Phoenix, Arizona 85014, USA.
| | | | | | | | | | | |
Collapse
|
25
|
Protus BM, Grauer PA, Kimbrel JM. Evaluation of Atropine 1% Ophthalmic Solution Administered Sublingually for the Management of Terminal Respiratory Secretions. Am J Hosp Palliat Care 2012; 30:388-92. [DOI: 10.1177/1049909112453641] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Terminal respiratory secretions (TRS) or “death rattle” is a common symptom in the dying patient. Current practice for the prevention and treatment of TRS involves the use of oral, sublingual, transdermal, or parenteral anticholinergic medications. A retrospective chart review of patients admitted to a hospice inpatient unit for terminal care and treated with sublingual atropine 1% ophthalmic drops for TRS was conducted. A total of 19 of 22 patients treated with atropine had documented reduction or resolution of TRS. This study suggests that atropine 1% ophthalmic drops administered sublingually are a reasonable option for the management of TRS. Problematic cardiac or central nervous system symptoms were not found in the present study. Results should aid hospice programs who are seeking guidance on the management of TRS with atropine 1% ophthalmic drops.
Collapse
Affiliation(s)
- Bridget McCrate Protus
- HospiScript Services, Dublin, OH, USA
- The Ohio State University, College of Pharmacy, Columbus, OH, USA
| | - Phyllis A. Grauer
- HospiScript Services, Dublin, OH, USA
- The Ohio State University, College of Pharmacy, Columbus, OH, USA
| | - Jason M. Kimbrel
- HospiScript Services, Dublin, OH, USA
- Ohio Northern University, College of Pharmacy, Ada, OH, USA
| |
Collapse
|
26
|
Shinjo T, Okada M. Atropine eyedrops for death rattle in a terminal cancer patient. J Palliat Med 2012; 16:212-3. [PMID: 22747099 DOI: 10.1089/jpm.2011.0537] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
"Death rattle" is a term used to describe the noisy sound produced by dying patients caused by the oscillatory movements of secretions in the upper airways. Antimuscarinic drugs, including atropine, scopolamine (hyoscine hydrobromide), hyoscine butylbromide, and glycopyrronium, have been used to diminish the noisy sound by reducing airway secretions. We report on the effectiveness of sublingual atropine eyedrops in alleviating death rattle in a terminal cancer patient. We present a 58-year-old man with pancreatic cancer who was admitted to our hospital because of severe dyspnea, cough, and death rattle with excessive bronchial secretion as a result of multiple lung metastases. We administered 1% atropine eyedrops sublingually to obviate the need for subcutaneous infusions and to prevent somnolence. On the basis of our experience, we conclude that atropine eyedrops, administered sublingually for distressing upper respiratory secretions, may be an effective alternative to the injection of antimuscarinic drugs, or as an option when other antimuscarinic formulations are not available.
Collapse
Affiliation(s)
- Takuya Shinjo
- Palliative Care Unit, Shakaihoken Kobe Central Hospital, Kobe, Hyogo, Japan.
| | | |
Collapse
|
27
|
Jakabová S, Vincze L, Farkas Á, Kilár F, Boros B, Felinger A. Determination of tropane alkaloids atropine and scopolamine by liquid chromatography–mass spectrometry in plant organs of Datura species. J Chromatogr A 2012; 1232:295-301. [DOI: 10.1016/j.chroma.2012.02.036] [Citation(s) in RCA: 80] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2011] [Revised: 02/14/2012] [Accepted: 02/14/2012] [Indexed: 11/16/2022]
|